Novo Nordisk AS (Novo Nordisk), a subsidiary of Novo Holdings AS, discovers, develops, manufactures, markets, and distributes products for diabetes, obesity and rare blood and endocrine diseases. The company also provides treatment for growth disorders, haemophilia, sickle cell disease, metabolic dysfunction-associated steatohepatitis (MASH), cardiovascular disease and Alzheimer's disease.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Novo Nordisk conducts R&D to engineer proteins into safe and effective therapies and develop new and improved delivery systems. The company uses biotechnological methods based on protein engineering and advanced protein chemistry in its research. The company's R&D centers drive innovation in diabetes and rare diseases. In Malov, Denmark, it focuses on protein and peptide engineering, while Bagsvaerd manages drug candidate development and safety surveillance. Soborg Center conducts late-stage development across therapy areas. Hillerod is dedicated to device innovation, and Oxford focuses on disruptive therapies for cardiometabolic diseases. In Seattle, digital therapy and AI are the focus, while Fremont specializes in stem cell-based products and Boulder in oligonucleotide therapeutics. Lexington houses RNAi innovation, and Watertown focuses on rare hematologic diseases and cancers. Novo Nordisk is developing treatments for people living with diabetes, obesity, rare blood disorders, hemophilia, endocrine disorders, growth disorders and other chronic diseases such as NASH, Alzheimer’s disease, sickle cell disease, kidney disease, Parkinson’s disease, and cardiovascular diseases. In FY2023, the company spent DKK32,443 million on its R&D which as a percentage of revenue stood at 13.9%, and grew 34.9% YoY. The company operates five R&D sites in Denmark, the UK, the US, China and India. Its core R&D capabilities include engineering, formulating, developing and delivering. The company has R&D collaborations with several biotech companies, including BioLamina, Kallyope, Emisphere, and Adimab; and universities including Lunds University, University of California San Francisco to accelerate innovation from partnerships to patients and attract top talents to its global R&D sites.